[Prostaglandins in cardiovascular and renal function. Biochemical, physiological and clinical findings (author's transl)].
Prostaglandins (PG) are highly unsaturated, cyclic fatty acids with 20 carbon atoms which are biosynthesized from dihomo-gamma-linolenic, arachidonic and eicosapentaenoic acids. These fatty acids are either ingested or are biosynthesized from linoleic and linolenic acids, respectively. The PG-precursor fatty acids are liberated from membrane phospholipids by phospholipase A and are converted to prostaglandins by the multienzyme complex PG-synthetase. The activity of the PG-system is influenced by extracellular hormonal, neural and mechanical stimuli and by intracellular factors such as ion-concentration and activity of the enzymes adenyl- and guanylcyclase. Prostaglandins are tissue hormones or autacoids which act on their receptors near their site of synthesis and degradation. The prostaglandin family constitutes a group of more than 10 natural occurring compounds showing a variety of biological actions. In arteries and veins the different PG:s have vasodilating as well as vasoconstricting effects. In addition, they are involved in the regulation of vascular smooth muscle proliferation. Within the kidney PG:s have vascular and tubular actions. They antagonize the effect of ADH, mediate renin secretion and are involved in the control of electrolyte balance. In the regulation of platelet aggregation and platelet adhesion PG:s have opposite functions: Prostacyclin which is synthesized in the vascular wall antagonizes the aggregating action of Thromboxane A2 which is formed in the platelets. A defect or an imbalance in the production of PG:s in the vascular wall, in platelets or in the kidney is assumed to play a pathogenetic role in a variety of cardiovascular and renal diseases such as in hypertension, atherosclerosis, persistent ductus arteriosus and Bartter's syndrome.
D001161:Arteriosclerosis / Q000503:physiopathology; D001477:Bartter Syndrome / Q000503:physiopathology; D001792:Blood Platelets / Q000502:physiology*; D001808:Blood Vessels / Q000502:physiology*; D004347:Drug Interactions; D004374:Ductus Arteriosus, Patent / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism* / Q000502:physiology; D009626:Terminology as Topic
D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011451:Prostaglandin-Endoperoxide Synthases
Vaskuläre, thrombozytäre und renale Prostaglandine. Biochemie, Funktion, klinische Aspekte.